Diabetes care provision and glycaemic control in Northern Ireland: a UK regional audit

C R Cardwell1, C C Patterson, M Allen

  • 1Department of Epidemiology & Public Health, The Queen's University of Belfast, UK. c.cardwell@qub.ac.uk

Insights

Most children with type 1 diabetes in Northern Ireland do not meet recommended glycaemic control targets. Membership in Diabetes UK was linked to better blood sugar control in pediatric patients.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Public Health

Background:

  • Type 1 diabetes management in children requires adherence to national guidelines for optimal health outcomes.
  • Glycaemic control is a critical factor in preventing long-term complications of type 1 diabetes.
  • Assessing current care standards against guidelines is essential for identifying areas of improvement.

Purpose of the Study:

  • To evaluate the quality of care for pediatric patients with type 1 diabetes in Northern Ireland against established national guidelines.
  • To identify factors influencing glycaemic control (measured by HbA1c) in this population.

Main Methods:

  • A 2002 audit of 11 pediatric diabetes clinics in Northern Ireland.
  • Interviews with 914 patients using questionnaires on demographics, social factors, and diabetes management.
  • Glycosylated haemoglobin (HbA1c) measurement at a central laboratory.

Main Results:

  • Average HbA1c was 8.8%, with only 20% achieving the target of <7.5%.
  • 76% received specialist nurse review; 42% were tested for microalbuminuria.
  • Better glycaemic control correlated with attending four clinics annually, Diabetes UK membership, and living with both biological parents.

Conclusions:

  • A minority of pediatric patients in Northern Ireland achieve recommended HbA1c levels.
  • Care and monitoring for microvascular complications fall short of national recommendations.
  • Membership in Diabetes UK suggests parental involvement positively impacts glycaemic control.
Abstract

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...